Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fennec Pharmaceuticals (TSE:FRX)
TSX:FRX
RESEARCH TOOLSreports
Holding TSE:FRX?
Track your performance easily
FRX Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$5.65 - C$17.00
Previous CloseC$6.5
Volume2.54K
Average Volume (3M)2.32K
Market Cap
C$156.06M
Enterprise ValueC$137.51M
Total Cash (Recent Filing)$43.05M
Total Debt (Recent Filing)$29.77M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Apr 01, 2025EPS Estimate
-C$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding27,329,000
10 Day Avg. Volume2,537
30 Day Avg. Volume2,321
Standard Deviation0.15
R-Squared0.01
Alpha0.00766
Financial Highlights & Ratios
Price to Book (P/B)-130.00
Price to Sales (P/S)2.35
Price to Cash Flow (P/CF)-3.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.69
Enterprise Value/Gross Profit6.88
Enterprise Value/Ebitda20.31
Forecast
1Y Price Target
C$19.56Price Target Upside196.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Fennec Pharmaceuticals News
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Strong Q3 Results
PremiumCompany Announcements
Fennec Pharmaceuticals Reports Q3 2024 Financial Results
PremiumCompany Announcements
Fennec Pharmaceuticals Strengthens Leadership Team for GrowthBulls Say, Bears Say
Bulls Say
Leadership And InnovationThe appointment of Jeffrey S. Hackman as the new CEO, with over 30 years of commercial leadership experience, brings strategic expertise to drive Fennec's growth, especially in transitioning products to the adolescent and young adult population.
Market ExpansionPositive early signals of momentum are emerging as Fennec focuses on the adolescent and young adult (AYA) market, with expectations of growth from increased penetration and reduced off-label generic use due to the new J code.
Product LaunchNorgine remains on track to launch Pedmarqsi in Germany, anticipating a first milestone of $10MM following pricing negotiations, which highlights the potential for significant revenue growth in the European market.
Bears Say
Product RevenueThe company recorded product revenue totaling only $7.3M, which actually represented a modest quarter-over-quarter decline vs. 1Q24.
Revenue GrowthRevenue on the pediatric side has been somewhat modest, leading to reduced growth projections for this segment.
Sales ExpectationsPedmark net sales for the quarter were $7.3MM (-2% q/q), in line with COS estimates ($7.5MM) but below Street expectations ($8.3MM).
---
Options Prices
Currently, No data available
---
Ownership Overview
3.26% Insiders
5.37% Mutual Funds
― Other Institutional Investors
84.36% Public Companies and
Individual Investors
FRX FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was C$5.65 and its highest was C$17.00 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Currently, no data Available
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Apr 01, 2025 which is in 130 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -C$0.293 earnings per share for the quarter, missing the consensus estimate of -C$0.126 by -C$0.168.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is -C$0.15.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 27,427,704 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of -C$0.293 in its last earnings report, missing expectations of -C$0.126. Following the earnings report the stock price went down -11.37%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in TSE:FRX
---
Fennec Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$19.56 (196.83% Upside)
C$19.56 (196.83% Upside)
Blogger Sentiment
Bullish
TSE:FRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
209.65%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development of sodium thiosulfate for the prevention of ototoxicity from cisplatin in pediatric cancer patients. The company was founded by Orest W. Blaschuk on September 3, 1996 and is headquartered in Durham, NC.
---
FRX Earnings Call
Q3 2024
0:00 / 0:00
---
FRX Stock 12 Month Forecast
Average Price Target
C$19.56
▲(196.83% Upside)
Technical Analysis
Fennec Pharmaceuticals
―
ADMA Biologics
―
Aldeyra Therapeutics
―
ESSA Pharma
―
Karyopharm Therapeutics
―
Best Analysts Covering FRX
1 Year
1 Year Success Rate
5/14 ratings generated profit
1 Year Average Return
-16.89%
assigned a buy rating 14 days ago
Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 35.71% of your transactions generating a profit, with an average return of -16.89% per trade.
---